<p>根據 Jennison Associates LLC 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第四季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持倉減少了 37.3%。該公司在季度內出售了 763,133 股後，持有 1,281,601 股該公司的股票。根據其最近向證券交易委員會（SEC）提交的文件，Jennison Associates LLC 持有的 Crinetics Pharmaceuticals 約佔 1.35%，價值 59,659,000 美元。</p>
<p>其他一些對沖基金也調整了對 CRNX 的持倉。Headlands Technologies LLC 在第二季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值約 30,000 美元。Farther Finance Advisors LLC 在第三季度將其在 Crinetics Pharmaceuticals 的持倉增加了 523.7%。Farther Finance Advisors LLC 現在持有 842 股該公司的股票，價值 35,000 美元，此前在上個季度又購買了 707 股。Raymond James Financial Inc.在第二季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值 45,000 美元。Covestor Ltd 在第三季度將其在 Crinetics Pharmaceuticals 的持倉增加了 23,983.3%。Covestor Ltd 現在持有 1,445 股該公司的股票，價值 60,000 美元，此前在上個季度又購買了 1,439 股。最後，Abich Financial Wealth Management LLC 在第三季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值 68,000 美元。目前 98.51% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>CRNX 已成為幾份研究分析師報告的主題。Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Crinetics Pharmaceuticals 股票的 “賣出（d-）” 評級。高盛集團在 1 月 12 日的報告中將 Crinetics Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。華爾街 Zen 在 3 月 28 日的報告中將 Crinetics Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。摩根士丹利在 1 月 6 日的報告中將 Crinetics Pharmaceuticals 的目標價從 77.00 美元提高到 80.00 美元，並給予該股票 “超配” 評級。最後，Lifesci Capital 在 2 月 13 日的報告中將 Crinetics Pharmaceuticals 的股票評級提升至 “強力買入”。一位研究分析師給予該股票 “強力買入” 評級，八位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價為 76.75 美元。</p>
<p><strong>查看我們對 Crinetics Pharmaceuticals 的最新股票分析</strong></p>
<h2>Crinetics Pharmaceuticals 股票上漲 0.9%</h2>
<p>Crinetics Pharmaceuticals 的股票在週五開盤價為 38.78 美元。該公司的市值為 40.6 億美元，市盈率為-7.85，貝塔值為 0.30。該公司的 50 日移動平均線為 38.52 美元，200 日移動平均線為 43.91 美元。Crinetics Pharmaceuticals, Inc.的 52 周低點為 25.83 美元，52 周高點為 57.99 美元。</p>
<p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 獲取免費報告）最近於 2 月 26 日發佈了季度財報。該公司報告季度每股收益（EPS）為（1.29 美元），超出分析師一致預期的（1.37 美元）0.08 美元。該季度的收入為 616 萬美元，而一致預期為 432 萬美元。Crinetics Pharmaceuticals 的淨利潤率為-6,046.22%，股本回報率為-41.46%。Crinetics Pharmaceuticals 的收入同比增長 NaN%。在去年同期，該公司每股收益為（0.88 美元）。平均而言，股票研究分析師預計 Crinetics Pharmaceuticals, Inc.在當前財年將發佈-4.95 的每股收益。</p>
<h2>Crinetics Pharmaceuticals 的內部活動</h2>
<p>在相關消息中，內部人士 Stephen F. Betz 於 3 月 16 日星期一出售了 10,612 股該公司的股票。股票以 37.37 美元的平均價格出售，總交易額為 396,570.44 美元。出售後，內部人士持有 137,101 股該公司的股票，價值 5,123,464.37 美元。這代表其持股減少了 7.18%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，首席執行官 Richard Scott Struthers 於 3 月 16 日星期一出售了 21,981 股該公司的股票。股票以 37.37 美元的平均價格出售，總交易額為 821,429.97 美元。出售後，首席執行官直接持有該公司 404,778 股，價值約 15,126,553.86 美元。該交易使其持股減少了 5.15%。該出售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 142,380 股公司股票，價值 5,569,475 美元。目前 4.60% 的股票由內部人士持有。</p>
<h2>Crinetics Pharmaceuticals 簡介</h2>
<p>（免費報告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以解決由激素活動失調引起的疾病。Crinetics 的研究工作集中在靶向生長抑素、抗利尿激素和其他 GPCR 介導的通路，旨在改善患者的便利性和依從性。</p>
<p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Crinetics Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
<p>在考慮 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
<p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRNX

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

<p>Jennison Associates LLC 已將其在 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) 的持股比例減少了 37.3%，在第四季度出售了 763,133 股。出售後，他們持有 1,281,601 股，估值約為 5966 萬美元。其他對沖基金也調整了在 CRNX 的持倉。分析師對該股票的評級不一，目前的平均評級為 “適度買入”，目標價格為 76.75 美元。Crinetics Pharmaceuticals 報告了季度每股虧損 1.29 美元，超出預期，營收為 616 萬美元</p>

<p>Jennison Associates LLC reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,281,601 shares of the company's stock after selling 763,133 shares during the quarter. Jennison Associates LLC owned approximately 1.35% of Crinetics Pharmaceuticals worth $59,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根據 Jennison Associates LLC 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第四季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持倉減少了 37.3%。該公司在季度內出售了 763,133 股後，持有 1,281,601 股該公司的股票。根據其最近向證券交易委員會（SEC）提交的文件，Jennison Associates LLC 持有的 Crinetics Pharmaceuticals 約佔 1.35%，價值 59,659,000 美元。</p>
</div><p>A number of other hedge funds have also modified their holdings of CRNX. Headlands Technologies LLC bought a new position in shares of Crinetics Pharmaceuticals in the second quarter worth approximately $30,000. Farther Finance Advisors LLC lifted its holdings in shares of Crinetics Pharmaceuticals by 523.7% in the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock worth $35,000 after buying an additional 707 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Crinetics Pharmaceuticals in the second quarter worth $45,000. Covestor Ltd lifted its holdings in shares of Crinetics Pharmaceuticals by 23,983.3% in the third quarter. Covestor Ltd now owns 1,445 shares of the company's stock worth $60,000 after buying an additional 1,439 shares in the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new position in shares of Crinetics Pharmaceuticals in the third quarter worth $68,000. 98.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金也調整了對 CRNX 的持倉。Headlands Technologies LLC 在第二季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值約 30,000 美元。Farther Finance Advisors LLC 在第三季度將其在 Crinetics Pharmaceuticals 的持倉增加了 523.7%。Farther Finance Advisors LLC 現在持有 842 股該公司的股票，價值 35,000 美元，此前在上個季度又購買了 707 股。Raymond James Financial Inc.在第二季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值 45,000 美元。Covestor Ltd 在第三季度將其在 Crinetics Pharmaceuticals 的持倉增加了 23,983.3%。Covestor Ltd 現在持有 1,445 股該公司的股票，價值 60,000 美元，此前在上個季度又購買了 1,439 股。最後，Abich Financial Wealth Management LLC 在第三季度購買了 Crinetics Pharmaceuticals 的新頭寸，價值 68,000 美元。目前 98.51% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>CRNX has been the topic of several research analyst reports. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group raised shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a report on Monday, January 12th. Wall Street Zen downgraded shares of Crinetics Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 28th. Morgan Stanley boosted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, January 6th. Finally, Lifesci Capital raised shares of Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $76.75.</p>
<div class="lb-trans"><p>CRNX 已成為幾份研究分析師報告的主題。Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Crinetics Pharmaceuticals 股票的 “賣出（d-）” 評級。高盛集團在 1 月 12 日的報告中將 Crinetics Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。華爾街 Zen 在 3 月 28 日的報告中將 Crinetics Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。摩根士丹利在 1 月 6 日的報告中將 Crinetics Pharmaceuticals 的目標價從 77.00 美元提高到 80.00 美元，並給予該股票 “超配” 評級。最後，Lifesci Capital 在 2 月 13 日的報告中將 Crinetics Pharmaceuticals 的股票評級提升至 “強力買入”。一位研究分析師給予該股票 “強力買入” 評級，八位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，平均目標價為 76.75 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Crinetics Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Crinetics Pharmaceuticals Stock Up 0.9%</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 股票上漲 0.9%</h2>
</div><p>Crinetics Pharmaceuticals stock opened at $38.78 on Friday. The company has a market cap of $4.06 billion, a price-to-earnings ratio of -7.85 and a beta of 0.30. The firm's fifty day moving average is $38.52 and its 200 day moving average is $43.91. Crinetics Pharmaceuticals, Inc. has a 52-week low of $25.83 and a 52-week high of $57.99.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals 的股票在週五開盤價為 38.78 美元。該公司的市值為 40.6 億美元，市盈率為-7.85，貝塔值為 0.30。該公司的 50 日移動平均線為 38.52 美元，200 日移動平均線為 43.91 美元。Crinetics Pharmaceuticals, Inc.的 52 周低點為 25.83 美元，52 周高點為 57.99 美元。</p>
</div><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.08. The company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. Crinetics Pharmaceuticals's revenue was up NaN% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. On average, equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -4.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 獲取免費報告）最近於 2 月 26 日發佈了季度財報。該公司報告季度每股收益（EPS）為（1.29 美元），超出分析師一致預期的（1.37 美元）0.08 美元。該季度的收入為 616 萬美元，而一致預期為 432 萬美元。Crinetics Pharmaceuticals 的淨利潤率為-6,046.22%，股本回報率為-41.46%。Crinetics Pharmaceuticals 的收入同比增長 NaN%。在去年同期，該公司每股收益為（0.88 美元）。平均而言，股票研究分析師預計 Crinetics Pharmaceuticals, Inc.在當前財年將發佈-4.95 的每股收益。</p>
</div><h2>Insider Activity at Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的內部活動</h2>
</div><p>In related news, insider Stephen F. Betz sold 10,612 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the sale, the insider owned 137,101 shares of the company's stock, valued at $5,123,464.37. This represents a 7.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Richard Scott Struthers sold 21,981 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $821,429.97. Following the sale, the chief executive officer directly owned 404,778 shares in the company, valued at approximately $15,126,553.86. The trade was a 5.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 142,380 shares of company stock valued at $5,569,475 over the last quarter. 4.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Stephen F. Betz 於 3 月 16 日星期一出售了 10,612 股該公司的股票。股票以 37.37 美元的平均價格出售，總交易額為 396,570.44 美元。出售後，內部人士持有 137,101 股該公司的股票，價值 5,123,464.37 美元。這代表其持股減少了 7.18%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，首席執行官 Richard Scott Struthers 於 3 月 16 日星期一出售了 21,981 股該公司的股票。股票以 37.37 美元的平均價格出售，總交易額為 821,429.97 美元。出售後，首席執行官直接持有該公司 404,778 股，價值約 15,126,553.86 美元。該交易使其持股減少了 5.15%。該出售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 142,380 股公司股票，價值 5,569,475 美元。目前 4.60% 的股票由內部人士持有。</p>
</div><h2>Crinetics Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以解決由激素活動失調引起的疾病。Crinetics 的研究工作集中在靶向生長抑素、抗利尿激素和其他 GPCR 介導的通路，旨在改善患者的便利性和依從性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Crinetics Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Market Beat

Crinetics Pharmaceuticals

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

醫藥突破 ETF - ALPS

標普全球醫療股指數 ETF - iShares

醫療業 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

基因改革 ETF - ARK

瑞傑金融

高盛

摩根士丹利

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Jennison Associates LLC 出售了 763,133 股 Crinetics Pharmaceuticals, Inc. 的股票 $CRNX